Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Breaking Down Learnings From TGW101 Unique PK & Improved Safety Profile & Application to Next Generation Click-Cleavable ADCs

Breaking Down Learnings From TGW101 Unique PK & Improved Safety Profile & Application to Next Generation Click-Cleavable ADCs

12:00 pm - Monday 12th October 2026

Breaking down rationale and mechanism for click-to-release chemistry to develop ADCs with reduced off-target toxicity
Highlighting key toxicity and PK aspects from the TGW101 program to support the safety benefits of the Click-to-Release ADC approach
Bringing learnings from TGW101 improved safety profile to ongoing ADC discovery across targets, protein formats and payloads to advance click-cleavable ADCs with mechanism-driven improved tolerability and therapeutic index

Speakers:

Marc Robillard

Marc Robillard

CSO and Founder

Tagworks Pharmaceuticals BV